Chimeric antigen receptor T cells march into T cell malignancies.
CAR-T
CAR-T product contamination
Fratricide
T cell aplasia
T cell malignancies
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
07
07
2023
accepted:
09
07
2023
pubmed:
20
7
2023
medline:
20
7
2023
entrez:
19
7
2023
Statut:
ppublish
Résumé
T cell malignancies represent a diverse collection of leukemia/lymphoma conditions in humans arising from aberrant T cells. Such malignancies are often associated with poor clinical prognoses, cancer relapse, as well as progressive resistance to anti-cancer treatments. While chimeric antigen receptor (CAR) T cell immunotherapy has emerged as a revolutionary treatment strategy that is highly effective for treating B cell malignancies, its application as a treatment for T cell malignancies remains to be better explored. Furthermore, the effectiveness of CAR-T treatment in T cell malignancies is significantly influenced by the quality of contamination-free CAR-T cells during the manufacturing process, as well as by multiple characteristics of such malignancies, including the sharing of antigens across normal and malignant T cells, fratricide, and T cell aplasia. In this review, we provide a detailed account of the current developments in the clinical application of CAR-T therapy to treat T cell malignancies, offer strategies for addressing current challenges, and outline a roadmap toward its effective implementation as a broad treatment option for this condition.
Identifiants
pubmed: 37468610
doi: 10.1007/s00432-023-05148-5
pii: 10.1007/s00432-023-05148-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
13459-13475Subventions
Organisme : National Natural Science Foundation of China
ID : No. 82172701
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Abou-El-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P et al (2021) Scalable manufacturing of CAR T cells for cancer immunotherapy. Blood Cancer Discov 2(5):408–422
pubmed: 34568831
pmcid: 8462122
Adikusuma F, Piltz S, Corbett MA, Turvey M, McColl SR, Helbig KJ et al (2018) Large deletions induced by Cas9 cleavage. Nature 560(7717):E8-e9
pubmed: 30089922
Ahn JS, Konno A, Gebe JA, Aruffo A, Hamilton MJ, Park YH, Davis WC (2002) Scavenger receptor cysteine-rich domains 9 and 11 of WC1 are receptors for the WC1 counter receptor. J Leukoc Biol 72(2):382–390
pubmed: 12149430
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36(7):1720–1748
pubmed: 35732829
pmcid: 9214472
Albinger N, Hartmann J, Ullrich E (2021) Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther 28(9):513–527
pubmed: 33753909
pmcid: 8455322
Azzam HS, Grinberg A, Lui K, Shen H, Shores EW, Love PE (1998) CD5 expression is developmentally regulated by T cell receptor (TCR) signals and TCR avidity. J Exp Med 188(12):2301–2311
pubmed: 9858516
pmcid: 2212429
Bárcena A, Muench MO, Roncarolo MG, Spits H (1995) Tracing the expression of CD7 and other antigens during T- and myeloid-cell differentiation in the human fetal liver and thymus. Leuk Lymphoma 17(1–2):1–11
pubmed: 7539656
Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M et al (2011) Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther 22(12):1575–1586
pubmed: 21838572
pmcid: 3237694
Bassan R, Maino E, Cortelazzo S (2016) Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment. Eur J Haematol 96(5):447–460
pubmed: 26679753
Bonilla FA, Kokron CM, Swinton P, Geha RS (1997) Targeted gene disruption of murine CD7. Int Immunol 9(12):1875–1883
pubmed: 9466315
Boumsell L, Gouttefangeas C, Dastot H, Schmid M, Gelin C, Bensussan A (1991) Identification of CD3 associated T cell receptor as a diagnostic tool in T Cell acute lymphoblastic lymphoma or leukemia. Leuk Lymphoma 4(3):187–192
pubmed: 27458672
Branella GM, Spencer HT (2021) Natural receptor- and ligand-based chimeric antigen receptors: strategies using natural ligands and receptors for targeted cell killing. Cells 11:1
Brocker T, Karjalainen K (1995) Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med 181(5):1653–1659
pubmed: 7722445
Brossard C, Semichon M, Trautmann A, Bismuth G (2003) CD5 inhibits signaling at the immunological synapse without impairing its formation. J Immunol 170(9):4623–4629
pubmed: 12707340
Campana D, van Dongen JJ, Mehta A, Coustan-Smith E, Wolvers-Tettero IL, Ganeshaguru K, Janossy G (1991) Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia. Blood 77(7):1546–1554
pubmed: 1826223
Casucci M, Falcone L, Camisa B, Norelli M, Porcellini S, Stornaiuolo A et al (2018) Extracellular NGFR spacers allow efficient tracking and enrichment of fully functional CAR-T cells co-expressing a suicide gene. Front Immunol 9:507
pubmed: 29619024
pmcid: 5871667
Cazzola M (2016) Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. Blood 127(20):2361–2364
pubmed: 27069255
Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT et al (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15(17):5323–5337
pubmed: 19723653
pmcid: 5779623
Chen KH, Wada M, Firor AE, Pinz KG, Jares A, Liu H et al (2016) Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies. Oncotarget 7(35):56219–56232
pubmed: 27494836
pmcid: 5302909
Chen KH, Wada M, Pinz KG, Liu H, Lin KW, Jares A et al (2017) Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia 31(10):2151–2160
pubmed: 28074066
pmcid: 5629371
Chen D, You F, Xiang S, Wang Y, Li Y, Meng H et al (2021) Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies. Am J Cancer Res 11(11):5263–5281
pubmed: 34873460
pmcid: 8640809
Chen X, Wang D, Zhu X (2022) Application of double-negative T cells in haematological malignancies: recent progress and future directions. Biomark Res 10(1):11
pubmed: 35287737
pmcid: 8919567
Chetty R, Gatter K (1994) CD3: structure, function, and role of immunostaining in clinical practice. J Pathol 173(4):303–307
pubmed: 7525907
Chinen J, Shearer WT (2010) Secondary immunodeficiencies, including HIV infection. J Allergy Clin Immunol 125(2 Suppl 2):S195-203
pubmed: 20042227
Chmielewski M, Abken H (2015) TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther 15(8):1145–1154
pubmed: 25985798
Cooper ML, Choi J, Staser K, Ritchey JK, Devenport JM, Eckardt K et al (2018) An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia 32(9):1970–1983
pubmed: 29483708
pmcid: 6102094
Daher M, Rezvani K (2018) Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol 51:146–153
pubmed: 29605760
pmcid: 6140331
Dai HP, Cui W, Cui QY, Zhu WJ, Meng HM, Zhu MQ et al (2022a) Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma. Biomark Res 10(1):6
pubmed: 35130959
pmcid: 8822664
Dai Z, Mu W, Zhao Y, Cheng J, Lin H, Ouyang K et al (2022b) T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape. Signal Transduct Target Ther 7(1):85
pubmed: 35332132
pmcid: 8948246
Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L (2020) “Off-the-shelf” allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov 19(3):185–199
pubmed: 31900462
Diaconu I, Ballard B, Zhang M, Chen Y, West J, Dotti G, Savoldo B (2017) Inducible caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T Cells. Mol Ther 25(3):580–592
pubmed: 28187946
pmcid: 5363196
Diorio C, Murray R, Naniong M, Barrera L, Camblin A, Chukinas J et al (2022) Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL. Blood 140(6):619–629
pubmed: 35560156
pmcid: 9373016
Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM et al (2010) Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 28(23):3730–3738
pubmed: 20625136
pmcid: 2917308
Facciabene A, Motz GT, Coukos G (2012) T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 72(9):2162–2171
pubmed: 22549946
pmcid: 3342842
Fischer A, Notarangelo LD, Neven B, Cavazzana M, Puck JM (2015) Severe combined immunodeficiencies and related disorders. Nat Rev Dis Primers 1:15061
pubmed: 27189259
Fleischer LC, Spencer HT, Raikar SS (2019) Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions. J Hematol Oncol 12(1):141
pubmed: 31884955
pmcid: 6936092
Fu XR, Wan WJ, Sun ZC, Zhang XD, Nan FF, Ge JR et al (2020) Expression of CD7 and its correlation with prognosis in patients with NK/T-cell lymphoma. Zhonghua Xue Ye Xue Za Zhi 41(11):921–926
pubmed: 33333695
Gaudelli NM, Komor AC, Rees HA, Packer MS, Badran AH, Bryson DI, Liu DR (2017) Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature 551(7681):464–471
pubmed: 29160308
pmcid: 5726555
Głowacki P, Rieske P (2022) Application and design of switches used in CAR. Cells 11:12
Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L (2004) NKT cells: what’s in a name? Nat Rev Immunol 4(3):231–237
pubmed: 15039760
Golubovskaya V, Wu L (2016) Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy. Cancers (basel) 8:3
Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH et al (2017) CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood 130(3):285–296
pubmed: 28539325
pmcid: 5520470
Gouttefangeas C, Bensussan A, Boumsell L (1990) Study of the CD3-associated T-cell receptors reveals further differences between T-cell acute lymphoblastic lymphoma and leukemia. Blood 75(4):931–934
pubmed: 2302460
Hamieh M, Dobrin A, Cabriolu A, van der Stegen SJC, Giavridis T, Mansilla-Soto J et al (2019) CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568(7750):112–116
pubmed: 30918399
pmcid: 6707377
Harper T, Sharma A, Kaliyaperumal S, Fajardo F, Hsu K, Liu L et al (2022) Characterization of an Anti-CD70 half-life extended bispecific T-cell engager (HLE-BiTE) and associated on-target toxicity in cynomolgus monkeys. Toxicol Sci 189(1):32–50
pubmed: 35583313
Hodgins JJ, Khan ST, Park MM, Auer RC, Ardolino M (2019) Killers 2.0: NK cell therapies at the forefront of cancer control. J Clin Invest 129(9):3499–3510
pubmed: 31478911
pmcid: 6715409
Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Pohl C, Abken H (1998) An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin’s lymphoma cells in the presence of soluble CD30. Cancer Res 58(6):1116–1119
pubmed: 9515791
Hu Y, Zhou Y, Zhang M, Zhao H, Wei G, Ge W et al (2022) Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res 32(11):995–1007
pubmed: 36151216
Huang J, Alexey S, Li J, Jones T, Grande G, Douthit L et al (2019) Unique CDR3 epitope targeting by CAR-T cells is a viable approach for treating T-cell malignancies. Leukemia 33(9):2315–2319
pubmed: 30962578
Ihry RJ, Worringer KA, Salick MR, Frias E, Ho D, Theriault K et al (2018) p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nat Med 24(7):939–946
pubmed: 29892062
Jan M, Scarfò I, Larson RC, Walker A, Schmidts A, Guirguis AA et al (2021) Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. Sci Transl Med 13:575
Jiang W, He Y, He W, Wu G, Zhou X, Sheng Q et al (2020) Exhausted CD8+T cells in the tumor immune microenvironment: new pathways to therapy. Front Immunol 11:622509
pubmed: 33633741
June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) CAR T cell immunotherapy for human cancer. Science 359(6382):1361–1365
pubmed: 29567707
Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K et al (2018) A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med 24(3):352–359
pubmed: 29400710
pmcid: 5839992
Kamiya T, Wong D, Png YT, Campana D (2018) A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells. Blood Adv 2(5):517–528
pubmed: 29507075
pmcid: 5851418
Knox SJ, Levy R, Hodgkinson S, Bell R, Brown S, Wood GS et al (1991) Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. Blood 77(1):20–30
pubmed: 1984796
Knox S, Hoppe RT, Maloney D, Gibbs I, Fowler S, Marquez C et al (1996) Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 87(3):893–899
pubmed: 8562959
Kweon S, Phan MT, Chun S, Yu H, Kim J, Kim S et al (2019) Expansion of human NK cells using K562 cells expressing OX40 ligand and short exposure to IL-21. Front Immunol 10:879
pubmed: 31105701
pmcid: 6491902
Lameris R, Ruben JM, Iglesias-Guimarais V, de Jong M, Veth M, van de Bovenkamp FS et al (2023) A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies. Cell Rep Med 4(3):100961
pubmed: 36868236
pmcid: 10040383
Li F, Zhang H, Wang W, Yang P, Huang Y, Zhang J et al (2022) T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies. Nat Commun 13(1):4334
pubmed: 35882880
pmcid: 9325690
Litzow MR, Ferrando AA (2015) How I treat T-cell acute lymphoblastic leukemia in adults. Blood 126(7):833–841
pubmed: 25966987
Liu Q, Xu Y, Mou J, Tang K, Fu X, Li Y et al (2020) Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19(+) malignancy in a mouse model. Cytotherapy 22(10):552–562
pubmed: 32747298
Liu Y, Li W, Wang L, Ba M, Wang Q, Lu P et al (2021) Naturally selected anti-CD7 CAR-T cells without additional genetic manipulations as a potentially superior therapy for T-cell malignancies. Blood 138(Supplement 1):1696–1696
Lu J, Jiang G (2022) The journey of CAR-T therapy in hematological malignancies. Mol Cancer 21(1):194
pubmed: 36209106
pmcid: 9547409
Lu P, Liu Y, Yang J, Zhang X, Yang X, Wang H et al (2022) Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial. Blood 140(4):321–334
pubmed: 35500125
Lucey DR, Dorsky DI, Nicholson-Weller A, Weller PF (1989) Human eosinophils express CD4 protein and bind human immunodeficiency virus 1 gp120. J Exp Med 169(1):327–332
pubmed: 2783333
Ma G, Shen J, Pinz K, Wada M, Park J, Kim S et al (2019) Targeting T cell malignancies using CD4CAR T-cells and implementing a natural safety switch. Stem Cell Rev Rep 15(3):443–447
pubmed: 30826931
Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC et al (2017) Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies. Nat Med 23(12):1416–1423
pubmed: 29131157
Maciocia NC, Burley A, Nannini F, Wawrzyniecka P, Neves M, Karpanasamy T et al (2021) Anti-CD21 chimeric antigen receptor (CAR)-T cells for t cell acute lymphoblastic leukaemia (T-ALL). Blood 138(Supplement 1):902–902
Maciocia PM, Wawrzyniecka PA, Maciocia NC, Burley A, Karpanasamy T, Devereaux S et al (2022) Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia. Blood 140(1):25–37
pubmed: 35507686
Mamonkin M, Rouce RH, Tashiro H, Brenner MK (2015) A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood 126(8):983–992
pubmed: 26056165
pmcid: 4543231
Mamonkin M, Mukherjee M, Srinivasan M, Sharma S, Gomes-Silva D, Mo F et al (2018) Reversible transgene expression reduces fratricide and permits 4–1BB costimulation of CAR T cells directed to T-cell malignancies. Cancer Immunol Res 6(1):47–58
pubmed: 29079655
Marasco WA, Haseltine WA, Chen SY (1993) Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci U S A 90(16):7889–7893
pubmed: 8356098
pmcid: 47248
Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA et al (2022) Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells. Nature 602(7897):503–509
pubmed: 35110735
pmcid: 9166916
Mina A, Pro B (2022) T time: emerging and new therapies for peripheral T-cell lymphoma. Blood Rev 52:100889
pubmed: 34716031
Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18(4):843–851
pubmed: 20179677
pmcid: 2862534
Mulvey E, Ruan J (2020) Biomarker-driven management strategies for peripheral T cell lymphoma. J Hematol Oncol 13(1):59
pubmed: 32448357
pmcid: 7245625
Muro R, Takayanagi H, Nitta T (2019) T cell receptor signaling for γδT cell development. Inflamm Regen 39:6
pubmed: 30976362
pmcid: 6437992
Naso MF, Tomkowicz B, Perry WL 3rd, Strohl WR (2017) Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs 31(4):317–334
pubmed: 28669112
pmcid: 5548848
Nawaz W, Huang B, Xu S, Li Y, Zhu L, Yiqiao H et al (2021) AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia. Blood Cancer J 11(6):119
pubmed: 34162832
pmcid: 8222347
Nyberg WA, Ark J, To A, Clouden S, Reeder G, Muldoon JJ et al (2023) An evolved AAV variant enables efficient genetic engineering of murine T cells. Cell 186(2):446-460.e419
pubmed: 36638795
Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W et al (2021) Donor-derived CD7 chimeric antigen receptor T Cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial. J Clin Oncol 39(30):3340–3351
pubmed: 34324392
Petersen CT, Hassan M, Morris AB, Jeffery J, Lee K, Jagirdar N et al (2018) Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists. Blood Adv 2(3):210–223
pubmed: 29386194
pmcid: 5812323
Pinz K, Liu H, Golightly M, Jares A, Lan F, Zieve GW et al (2016) Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells. Leukemia 30(3):701–707
pubmed: 26526988
Pinz KG, Yakaboski E, Jares A, Liu H, Firor AE, Chen KH et al (2017) Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells. Oncotarget 8(68):112783–112796
pubmed: 29348865
pmcid: 5762550
Png YT, Vinanica N, Kamiya T, Shimasaki N, Coustan-Smith E, Campana D (2017) Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv 1(25):2348–2360
pubmed: 29296885
pmcid: 5729624
Rabinovich PM, Komarovskaya ME, Wrzesinski SH, Alderman JL, Budak-Alpdogan T, Karpikov A et al (2009) Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes. Hum Gene Ther 20(1):51–61
pubmed: 19025415
pmcid: 2855249
Rabinowich H, Pricop L, Herberman RB, Whiteside TL (1994) Expression and function of CD7 molecule on human natural killer cells. J Immunol 152(2):517–526
pubmed: 7506726
Rafiq S, Hackett CS, Brentjens RJ (2020) Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol 17(3):147–167
pubmed: 31848460
Raikar SS, Fleischer LC, Moot R, Fedanov A, Paik NY, Knight KA et al (2018) Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines. Oncoimmunology 7(3):e1407898
pubmed: 29399409
Rasaiyaah J, Georgiadis C, Preece R, Mock U, Qasim W (2018) TCRαβ/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy. JCI Insight 3:13
Roselli E, Boucher JC, Li G, Kotani H, Spitler K, Reid K et al (2021) 4–1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. J Immunother Cancer 9:10
Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE et al (2018) Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med 24(10):1499–1503
pubmed: 30275568
pmcid: 6511988
Sabattini E, Bacci F, Sagramoso C, Pileri SA (2010) WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 102(3):83–87
pubmed: 21171509
Sánchez-Martínez D, Baroni ML, Gutierrez-Agüera F, Roca-Ho H, Blanch-Lombarte O, González-García S et al (2019) Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood 133(21):2291–2304
pubmed: 30796021
pmcid: 6554538
Savage PA, Klawon DEJ, Miller CH (2020) Regulatory T Cell Development. Annu Rev Immunol 38:421–453
pubmed: 31990619
Scarfò I, Ormhøj M, Frigault MJ, Castano AP, Lorrey S, Bouffard AA et al (2018) Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood 132(14):1495–1506
pubmed: 30089630
pmcid: 6172564
Shi J, Zhang Z, Cen H, Wu H, Zhang S, Liu J et al (2021) CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity. J Hematol Oncol 14(1):162
pubmed: 34627328
pmcid: 8502293
Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL et al (2019) GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood 133(7):697–709
pubmed: 30463995
pmcid: 6376281
Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I et al (2018) Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma. Blood 132(10):1022–1026
pubmed: 29925499
Takaba H, Takayanagi H (2017) The mechanisms of T cell selection in the thymus. Trends Immunol 38(11):805–816
pubmed: 28830733
Teachey DT, Pui CH (2019) Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol 20(3):e142–e154
pubmed: 30842058
pmcid: 9233195
Terstappen LW, Huang S, Picker LJ (1992) Flow cytometric assessment of human T-cell differentiation in thymus and bone marrow. Blood 79(3):666–677
pubmed: 1370641
Tu Z, Xiao R, Xiong J, Tembo KM, Deng X, Xiong M et al (2016) CCR9 in cancer: oncogenic role and therapeutic targeting. J Hematol Oncol 9:10
pubmed: 26879872
pmcid: 4754913
van der Stegen SJ, Hamieh M, Sadelain M (2015) The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov 14(7):499–509
pubmed: 26129802
pmcid: 6410718
Wada M, Zhang H, Fang L, Feng J, Tse CO, Zhang W et al (2020) Characterization of an anti-CD5 directed CAR T-cell against T-cell malignancies. Stem Cell Rev Rep 16(2):369–384
pubmed: 32008159
Watanabe N, Mo F, Zheng R, Ma R, Bray VC, van Leeuwen DG et al (2023) Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies. Mol Ther 31(1):24–34
pubmed: 36086817
Wei W, Ma H, Yang D, Sun B, Tang J, Zhu Y et al (2023) SECTM1-based CAR-T cells enriched with CD7low/negative subsets exhibit efficacy in CD7-positive malignancies. Blood Adv 7:2941
pubmed: 36848638
pmcid: 10320215
Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, Jaffe ES (2019) The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 133(16):1703–1714
pubmed: 30635287
pmcid: 6473500
Wood GS, Warner NL, Warnke RA (1983) Anti-Leu-3/T4 antibodies react with cells of monocyte/macrophage and Langerhans lineage. J Immunol 131(1):212–216
pubmed: 6408171
Wurbel MA, Malissen M, Guy-Grand D, Meffre E, Nussenzweig MC, Richelme M et al (2001) Mice lacking the CCR9 CC-chemokine receptor show a mild impairment of early T- and B-cell development and a reduction in T-cell receptor gammadelta(+) gut intraepithelial lymphocytes. Blood 98(9):2626–2632
pubmed: 11675330
Ye J, Jia Y, Tuhin IJ, Tan J, Monty MA, Xu N et al (2022) Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody. Mol Ther Oncolytics 24:719–728
pubmed: 35317521
pmcid: 8913247
Yin X, Yu H, Jin X, Li J, Guo H, Shi Q et al (2017) Human blood CD1c+ dendritic cells encompass CD5high and CD5low subsets that differ significantly in phenotype, gene expression, and functions. J Immunol 198(4):1553–1564
pubmed: 28087664
You F, Wang Y, Jiang L, Zhu X, Chen D, Yuan L et al (2019) A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia. Am J Cancer Res 9(1):64–78
pubmed: 30755812
pmcid: 6356925
Zhang H, Feng J, Zhang W, Chen Q, Cao Y, Pinz K et al (2019a) First-in-human CD4 CAR clinical trial on peripheral T-cell lymphoma. Blood 134(1):2881–2881
Zhang RY, Wei D, Liu ZK, Yong YL, Wei W, Zhang ZY et al (2019b) Doxycycline inducible chimeric antigen receptor T Cells targeting CD147 for hepatocellular carcinoma therapy. Front Cell Dev Biol 7:233
pubmed: 31681766
pmcid: 6798074
Zhang M, Chen D, Fu X, Meng H, Nan F, Sun Z et al (2022a) Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma. Clin Cancer Res 28(13):2830–2843
pubmed: 35435984
Zhang X, Jin X, Sun R, Zhang M, Lu W, Zhao M (2022b) Gene knockout in cellular immunotherapy: application and limitations. Cancer Lett 540:215736
pubmed: 35569695
Zhao Y, Zheng Z, Cohen CJ, Gattinoni L, Palmer DC, Restifo NP et al (2006) High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther 13(1):151–159
pubmed: 16140584
Zhao J, Lin Q, Song Y, Liu D (2018) Universal CARs, universal T cells, and universal CAR T cells. J Hematol Oncol 11(1):132
pubmed: 30482221
pmcid: 6257951
Zheng NS, Zhao XY, Wei D, Miao JL, Liu ZK, Yong YL et al (2022) CD147-specific chimeric antigen receptor T cells effectively inhibit T cell acute lymphoblastic leukemia. Cancer Lett 542:215762
pubmed: 35659513
Zhu J, Paul WE (2008) CD4 T cells: fates, functions, and faults. Blood 112(5):1557–1569
pubmed: 18725574
pmcid: 2518872
Zúñiga-Pflücker JC (2004) T-cell development made simple. Nat Rev Immunol 4(1):67–72
pubmed: 14704769